Halozyme Therapeutics, Clinical Development and Translational Medicine, 11388 Sorrento Valley Road, San Diego, CA 92121, United States.
The Westmead Institute for Medical Research, University of Sydney, Australia.
Curr Opin Immunol. 2019 Aug;59:42-48. doi: 10.1016/j.coi.2019.02.009. Epub 2019 Apr 17.
Herpes zoster is common in older and immune suppressed persons due to diminished VZV-specific cellular immunity. A recombinant herpes zoster vaccine (RZV) consisting of a single VZV glycoprotein and an adjuvant system stimulates robust and persistent VZV-specific antibody and CD4+ T cell responses in these high-risk populations. VZV-specific immune responses induced by RZV, including the generation of polyfunctional T cells, are driven by the synergistic actions of the components of the vaccine adjuvant system. RZV provides unprecedented protection against herpes zoster in older adults regardless of age at vaccination and is efficacious in immune suppressed populations. Adjuvanted subunit antigens may represent a general strategy for vaccines in the elderly and other individuals typically considered immunologically resistant to vaccination.
带状疱疹在老年人和免疫抑制人群中很常见，这是由于 VZV 特异性细胞免疫减弱所致。一种由单一 VZV 糖蛋白和佐剂系统组成的重组带状疱疹疫苗（RZV）可在这些高危人群中刺激强烈和持久的 VZV 特异性抗体和 CD4+T 细胞反应。RZV 诱导的 VZV 特异性免疫反应，包括多能 T 细胞的产生，是由疫苗佐剂系统成分的协同作用驱动的。RZV 为老年人提供了前所未有的带状疱疹保护，无论接种疫苗时的年龄如何，并且在免疫抑制人群中有效。佐剂亚单位抗原可能代表了老年人和其他通常被认为对疫苗有免疫抵抗的人群疫苗的一般策略。
